These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32476509)

  • 41. Genetic and epigenetic mechanisms of NASH.
    Eslam M; George J
    Hepatol Int; 2016 May; 10(3):394-406. PubMed ID: 26683320
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of
    Toda-Oti KS; Stefano JT; Cavaleiro AM; Carrilho FJ; Correa-Gianella ML; Oliveira CPMS
    Metab Syndr Relat Disord; 2022 Mar; 20(2):114-123. PubMed ID: 35020496
    [No Abstract]   [Full Text] [Related]  

  • 45. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.
    Gallego-Durán R; Romero-Gómez M
    World J Hepatol; 2015 Oct; 7(24):2497-502. PubMed ID: 26523202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dietary Patterns Influence Target Gene Expression through Emerging Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.
    Zaiou M; Amrani R; Rihn B; Hajri T
    Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: effect of dietary methyl donor supplementation.
    Cordero P; Campion J; Milagro FI; Martinez JA
    Mol Genet Metab; 2013 Nov; 110(3):388-95. PubMed ID: 24084163
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease.
    Aguilar-Olivos NE; Oria-Hernández J; Ponciano-Rodríguez G; Chávez-Tapia NC; Uribe M; Méndez-Sánchez N
    Mini Rev Med Chem; 2015; 15(14):1187-94. PubMed ID: 26156419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis.
    Hwang S; Yun H; Moon S; Cho YE; Gao B
    Front Endocrinol (Lausanne); 2021; 12():751802. PubMed ID: 34707573
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Future of Nonalcoholic Fatty Liver Disease Treatment.
    Mazhar K
    Med Clin North Am; 2019 Jan; 103(1):57-69. PubMed ID: 30466676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications.
    Pirola CJ; Sookoian S
    Curr Opin Lipidol; 2022 Apr; 33(2):95-102. PubMed ID: 34966133
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease.
    Ziolkowska S; Binienda A; Jabłkowski M; Szemraj J; Czarny P
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
    Radwan MM; Radwan BM; Nandipati KC; Hunter WJ; Agrawal DK
    Expert Rev Clin Immunol; 2013 Aug; 9(8):727-38. PubMed ID: 23971751
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
    Francque S; Szabo G; Abdelmalek MF; Byrne CD; Cusi K; Dufour JF; Roden M; Sacks F; Tacke F
    Nat Rev Gastroenterol Hepatol; 2021 Jan; 18(1):24-39. PubMed ID: 33093663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Review article: shared disease mechanisms between non-alcoholic fatty liver disease and metabolic syndrome - translating knowledge from systems biology to the bedside.
    Sookoian S; Pirola CJ
    Aliment Pharmacol Ther; 2019 Mar; 49(5):516-527. PubMed ID: 30714632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The nonalcoholic fatty liver disease-like phenotype and lowered serum VLDL are associated with decreased expression and DNA hypermethylation of hepatic ApoB in male offspring of ApoE deficient mothers fed a with Western diet.
    Chen HC; Chen YZ; Wang CH; Lin FJ
    J Nutr Biochem; 2020 Mar; 77():108319. PubMed ID: 31926452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Non-alcoholic fatty liver disease: A review with clinical and pathological correlation.
    Chen YY; Yeh MM
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 1):68-77. PubMed ID: 32654868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.